DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Ebola Viral Infections - Pipeline Review, H1 2016" report to their offering.
The report provides comprehensive information on the therapeutics under development for Ebola Viral Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ebola Viral Infections and features dormant and discontinued projects.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision-making capabilities and helps to create effective counter-strategies to gain competitive advantage.
Scope:
- The report provides a snapshot of the global therapeutic landscape of Ebola Viral Infections.
- The report reviews pipeline therapeutics for Ebola Viral Infections by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages.
- The report reviews key players involved in Ebola Viral Infections therapeutics and lists all their major and minor projects.
- The report assesses Ebola Viral Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
- The report summarizes all the dormant and discontinued pipeline projects.
Companies Mentioned Include:
- Abivax S.A.
- AnGes MG, Inc.
- ANP Technologies, Inc.
- Arno Therapeutics, Inc.
- Avipero Limited
- BioCryst Pharmaceuticals, Inc.
- BioFactura, Inc.
- Celgene Corporation
- Emergent BioSolutions Inc.
- Enyo Pharma S.A.S.
- Etubics Corporation
- GeoVax Labs, Inc.
- Gilead Sciences, Inc.
- Kineta, Inc.
- Kymab Limited
- Merck & Co., Inc.
- Microbiotix, Inc.
- Micropharm Limited
- NanoViricides, Inc.
- Soligenix, Inc.
- Taiga Biotechnologies, Inc.
- Tamir Biotechnology, Inc.
- TGV-Laboratories
- Toyama Chemical Co., Ltd.
- Vaxeal Holding SA
- XBiotech USA, Inc.
For more information visit http://www.researchandmarkets.com/research/t9cbh5/ebola_viral.
